Is Disc Medicine profitable?

Disc Medicine is not currently profitable: it reported a net loss of $241.6M over the trailing twelve months.

What is Disc Medicine's earnings per share?

Disc Medicine's diluted EPS over the trailing twelve months is $-6.62.

Where does Disc Medicine's income statement data come from?

Every line is extracted from Disc Medicine's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Disc Medicine IRON Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	$188.78M+87.4%	$170.64M+76.5%	$149.21M+58.0%	$123.56M+46.8%	$100.73M+38.4%
Selling, general and administrative	$76.82M+105%	$65.38M+97.8%	$54.39M+89.1%	$45.2M+73.5%	$37.47M+55.1%
Other operating expenses	$265.6M+92.2%	$236.02M+81.9%	$203.6M+63.0%	$168.76M+52.1%	$138.2M+41.8%
Total operating expenses	$265.6M+92.2%	$236.02M+81.9%	$203.6M+63.0%	$168.76M+52.1%	$138.2M+41.8%
Interest expense	$3.55M+142%	$3.61M+531%	$3.3M—	$2.38M—	$1.47M—
Other income (expense), net	$24.29M+9.5%	$24.2M+16.8%	$22.94M+6.1%	$23.84M+18.6%	$22.18M+30.9%
Income tax expense	$293K-37.5%	$361K+1.7%	$449K+113%	$461K+294%	$469K+479%
Net income	-$241.6M-107%	-$212.18M-94.0%	-$181.11M-75.0%	-$145.39M-59.8%	-$116.49M-44.5%
Diluted earnings per share	-$6.62-68.9%	-$5.99-50.1%	-$5.35-34.4%	-$4.47-21.8%	-$3.92-16.0%
Basic earnings per share	-$6.62-68.9%	-$5.99-50.1%	-$5.35-34.4%	-$4.47-21.8%	-$3.92-16.0%
Weighted-average shares, diluted	144M+23.6%	138.8M+28.5%	131.1M+27.7%	125.9M+29.7%	116.5M+25.4%
Weighted-average shares, basic	144M+23.6%	138.8M+28.5%	131.1M+27.7%	125.9M+29.7%	116.5M+25.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$242.71M-109%	-$211.51M-93.9%	-$181.13M-76.3%	-$145.06M-59.3%	-$115.96M-43.9%
Accounts payable	$5.09M—	$1.07M—	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$230.85M-48.3%	$473.41M+117%	$285.53M+44.7%	$274.37M+39.1%	$446.67M+151%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	——	——	——	——	-$564.9M-444,702%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$201.25M-97.9%	-$180.39M-92.1%	-$164.67M-95.7%	-$134.23M-80.7%	-$101.7M-42.1%
Unrealized gains (losses) on available-for-sale securities	-$1.08M—	$677K—	——	——	——
Foreign currency translation gains (losses)	-$25K—	-$1K—	——	——	——
Other income, net (Note 6)	$72K—	$47K—	——	——	——
EBITDA	-$265.25M-92.1%	-$235.74M-81.9%	-$203.4M-63.1%	-$168.64M-52.2%	-$138.05M-41.8%
EBIT	-$265.6M-92.2%	-$236.02M-81.9%	-$203.6M-63.0%	-$168.76M-52.1%	-$138.2M-41.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Disc Medicine profitable?: Disc Medicine is not currently profitable: it reported a net loss of $241.6M over the trailing twelve months.
What is Disc Medicine's earnings per share?: Disc Medicine's diluted EPS over the trailing twelve months is $-6.62.
Where does Disc Medicine's income statement data come from?: Every line is extracted from Disc Medicine's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.